Status:
COMPLETED
Safety, Pharmacokinetics and Pharmacodynamics Study of HL-032 in Healthy Male Volunteers
Lead Sponsor:
HanAll BioPharma Co., Ltd.
Conditions:
Growth Hormone Deficiency
Eligibility:
MALE
19-50 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to evaluate the safety, pharmacokinetics and pharmacodynamics of HL-032 after oral administration in healthy male volunteers.
Eligibility Criteria
Inclusion
- Healthy male subjects
- Age(yr)between 19 and 50
- Signed written informed consent
Exclusion
- Known hypersensitivity to Octreotide or hGH(human growth hormone)
- History of Cardiovascular, Respiratory, Renal/Genitourinary, Gastrointestinal, Neurological/Psychic, cancer
- Alcoholic, smokers or drug abusers
- Other conditions which in the opinion of the investigator preclude enrollment into the study
Key Trial Info
Start Date :
September 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2012
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT01440686
Start Date
September 1 2011
End Date
January 1 2012
Last Update
October 16 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul National University Hospital,Clinical Trial Center/ Clinical Research Institute
Seoul, South Korea, 110-744